Bio

Akshay Nadkarni is involved in multiple activities across the firm ranging from leading full sell-side and buy-side M&A transactions to in-depth technology and corporate valuation analysis. Akshay has managed over 25 M&A transactions with a combined transaction value of over $1.2 billion over the past ten years. He is focused on grasping the key value drivers of international life science clients in order to identify creative strategic M&A opportunities. As part of the M&A team, Akshay has managed cross-border transactions involving companies in several healthcare and life science fields, including life science technologies/tools/reagents, in vitro diagnostics, molecular diagnostics, CRO and other outsourced life science services, biopharmaceuticals, specialty pharmaceuticals, generics and healthcare IT. In addition, he has undertaken research involving emerging companies in various healthcare and biotechnology sectors. Akshay holds a Bachelor of Arts in Biology and Finance from New York University.